clarithromycin has been researched along with bedaquiline in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Gevers, T; Lounis, N; Van den Berg, J; Vranckx, L | 1 |
| Andries, K; Bantubani, N; De Marez, T; Diacon, AH; Donald, PR; Grobusch, M; Lounis, N; Mahanyele, R; McNeeley, DF; Meyvisch, P; Narasimooloo, R; Patientia, RF; Pym, A; van Heeswijk, R | 1 |
| Andries, K; Arnett, KA; Creissen, E; Henao-Tamayo, M; Lenaerts, AJ; Massoudi, L; Obregón-Henao, A; Ordway, DJ | 1 |
| Aubry, A; Chauffour, A; Jarlier, V; Robert, J; Veziris, N | 1 |
| Jo, KW; Nam, GB; Shim, TS; Yoon, HY | 1 |
| Biewenga, J; Ernault, E; Kambili, C; Kurosawa, K; Ouwerkerk-Mahadevan, S; Rossenu, S; Willems, W | 1 |
2 trial(s) available for clarithromycin and bedaquiline
| Article | Year |
|---|---|
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.
Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Dapsone; Diarylquinolines; Erythromycin; Female; Humans; Isoxazoles; Male; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis, Multidrug-Resistant | 2012 |
Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Diarylquinolines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria | 2021 |
4 other study(ies) available for clarithromycin and bedaquiline
| Article | Year |
|---|---|
ATP synthase inhibition of Mycobacterium avium is not bactericidal.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Enzyme Inhibitors; Female; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium; Quinolines | 2009 |
Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models.
Topics: Animals; Anti-Bacterial Agents; Clarithromycin; Clofazimine; Diarylquinolines; Granulocyte-Macrophage Colony-Stimulating Factor; Mice; Mice, Knockout; Mice, SCID; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium Infections | 2015 |
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Diarylquinolines; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium ulcerans; Rifampin | 2016 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |